Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab
when given together in treating patients with non-Hodgkin lymphoma that has returned after a
period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances
made from living organisms that may stimulate or suppress the immune system in different ways
and stop cancer cells from growing. Blinatumomab is a monoclonal antibody that may interfere
with the ability of cancer cells to grow and spread.